Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 738.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,928 shares of the company's stock after purchasing an additional 106,498 shares during the quarter. Thrivent Financial for Lutherans owned about 0.39% of Medpace worth $40,176,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. R Squared Ltd acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace in the 4th quarter worth $31,000. Stone House Investment Management LLC purchased a new position in shares of Medpace during the 3rd quarter worth $33,000. Jones Financial Companies Lllp raised its holdings in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares during the period. Finally, Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Up 2.0 %

NASDAQ MEDP traded up $6.36 on Monday, reaching $330.59. The stock had a trading volume of 193,758 shares, compared to its average volume of 288,972. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock has a fifty day moving average price of $337.72 and a two-hundred day moving average price of $339.77. The firm has a market capitalization of $10.07 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 3.81 and a beta of 1.47.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MEDP shares. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a report on Monday. They set a "market perform" rating and a $330.00 price target for the company. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.